Peptobiotics

Peptobiotics, registered as Vaciome Pte. Ltd. and headquartered at 20 Biopolis Way, Centros Building, Singapore, develops recombinant antimicrobial peptides intended to replace antibiotics used in animal agriculture. The company describes its products as a new class of feed additives that inhibit pathogens and support gut health, feed conversion and growth with performance comparable to antibiotics but without driving bacterial resistance. It states its peptides have a mode of action that does not create resistance to themselves or to antibiotics, plus a host-dependent mechanism intended to improve intestinal health and feed uptake efficiency [0][2][3].

The underlying science draws on antimicrobial peptides, naturally occurring bacteria-inhibiting proteins that form a first line of immune defence in many organisms; the human genome alone is estimated to encode more than 100 distinct antimicrobial peptide genes. Commercialisation of such peptides has historically been limited by manufacturing cost, and Peptobiotics positions its contribution as biotechnology that lowers production costs for even complex peptides [6]. Products are formulated to remain active after feed pelleting and intestinal transit, allowing direct addition to feed or drinking water without encapsulation or spray coating, and are described as tasteless so that feed intake is unaffected [3].

The company is advancing both therapeutic and growth-promoting candidates across poultry, swine and shrimp aquaculture, with aquaculture as the initial commercial focus [2][5][6]. Coverage in November 2025 reported that Peptobiotics had delivered its first peptides to aquaculture facilities across Southeast Asia and that its lead product reached the market that year, while supply remained a bottleneck relative to demand [7].